Phenytoin chemical structure
Find information on thousands of medical conditions and prescription drugs.

Dilantin

Phenytoin sodium (marketed as Dilantin® in the USA and as Epanutin® in the UK, by Parke-Davis, now part of Pfizer) is a commonly used antiepileptic. It was approved by the Food and Drug Administration in 1953 for use in seizures. Phenytoin acts to damp the unwanted, runaway brain activity seen in seizure by reducing electrical conductance among brain cells. more...

Home
Diseases
Medicines
A
B
C
D
Dacarbazine
Dactinomycin
Dalmane
Danazol
Dantrolene
Dapoxetine
Dapsone
Daptomycin
Daraprim
Darvocet
Darvon
Daunorubicin
Daunorubicin
Daypro
DDAVP
Deca-Durabolin
Deferoxamine
Delsym
Demeclocycline
Demeclocycline
Demerol
Demulen
Denatonium
Depakene
Depakote
Depo-Provera
Desferal
Desflurane
Desipramine
Desmopressin
Desogen
Desogestrel
Desonide
Desoxyn
Desyrel
Detrol
Dexacort
Dexamethasone
Dexamfetamine
Dexedrine
Dexpanthenol
Dextran
Dextromethorphan
Dextromoramide
Dextropropoxyphene
Dextrorphan
Diabeta
Diacerein
Diacetolol
Dial
Diamox
Diazepam
Diazoxide
Dibenzepin
Diclofenac
Diclohexal
Didanosine
Dieldrin
Diethylcarbamazine
Diethylstilbestrol
Diethyltoluamide
Differin
Diflucan
Diflunisal
Digitoxin
Digoxin
Dihydrocodeine
Dihydroergotamine
Dihydrotachysterol
Dilantin
Dilaudid
Diltahexal
Diltiazem
Dimenhydrinate
Dimercaprol
Dimetapp
Dimethyl sulfoxide
Dimethyltryptamine
Dimetridazole
Diminazene
Diovan
Dioxybenzone
Diphenhydramine
Diphenoxylate
Dipipanone
Dipivefrine
Diprivan
Diprolene
Diproteverine
Dipyridamole
Disulfiram
Disulfiram
Dizocilpine
Dobutamine
Docetaxel
Docusate sodium
Dofetilide
Dolasetron
Dolobid
Dolophine
Domperidone
Donepezil
Dopamine
Dopram
Doral
Doramectin
Doriden
Dornase alfa
Doryx
Dostinex
Doxapram
Doxazosin
Doxepin
Doxil
Doxil
Doxorubicin
Doxy
Doxycycline
Doxyhexal
Doxylamine
Drisdol
Drixoral
Dronabinol
Droperidol
Drospirenone
Duloxetine
Durabolin
Duragesic
Duraphyl
Duraquin
Dutasteride
Dv
Dyclonine
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

History

Phenytoin (diphenylhydantoin) was first synthesized by a German physician named Heinrich Biltz in 1908. Biltz sold his discovery to Parke-Davis, which did not find an immediate use for it. In 1938, outside scientists including H. Houston Merritt and Tracy Putnam discovered phenytoin's usefulness for controlling seizures, without the sedation effects associated with phenobarbital. There are some indications that phenytoin has other effects, including anxiety control and mood stabilization, although it has never been approved for those purposes by the FDA.

Jack Dreyfus, founder of the Dreyfus Fund, became a major proponent of phenytoin as a means to control nervousness and depression when he received a prescription for Dilantin in 1966. Dreyfus' book about his experience with phenytoin, A Remarkable Medicine Has Been Overlooked, sits on the shelves of many physicians courtesy of the work of his foundation. Despite more than $70 million in personal financing, his push to see phenytoin evaluated for alternative uses has had little lasting effect on the medical community. This was partially due to Parke-Davis's reluctance to invest in a drug nearing the end of its patent life, and partially due to mixed results from various studies.

Dilantin made an appearance in the 1962 novel One Flew Over the Cuckoo's Nest by Ken Kesey, both as an anticonvulsant and as a mechanism to control inmate behavior.

Side-effects

At therapeutic doses, phenytoin produces horizontal gaze nystagmus, which is harmless but occasionally tested for by law enforcement as a marker for drunkenness (which can also produce nystagmus). At toxic doses, patients experience sedation, cerebellar ataxia, and ophthalmoparesis, as well as paradoxical seizures. Idiosyncratic side effects of phenytoin, as with other anticonvulsants, include rash and severe allergic reactions.

There is some evidence that phenytoin is teratogenic, causing what Smith and Jones in their Recognizable Patterns of Human Malformation called the fetal hydantoin syndrome. There is some evidence against this. One blinded trial asked physicians to separate photographs of children into two piles based on whether they showed the so-called characteristic features of this syndrome; it found that physicians were no better at diagnosing the syndrome than would be expected by random chance, calling the very existence of the syndrome into question. Data now being collected by the Epilepsy and Antiepileptic Drug Pregnancy Registry may one day answer this question definitively.

Phenytoin may accumulate in the cerebral cortex over long periods of time, as well as causing atrophy of the cerebellum when administered at chronically high levels. Despite this, the drug has a long history of safe use, making it one of the more popular anti-convulsants prescribed by doctors, and a common "first line of defense" in seizure cases. Phenytoin may also cause gingival hyperplasia.

Read more at Wikipedia.org


[List your site here Free!]


Case report: late-onset eclampsia presents as bilateral cortical blindness
From American Family Physician, 3/1/05 by Katherine J. Gold

TO THE EDITOR: Although preeclampsia is typically diagnosed in the prenatal period, we would like to describe an unusual case of late-onset eclampsia presenting postpartum as sudden bilateral cortical blindness.

The patient was a healthy, 21-year-old black woman, gravida three, para one, with a previous normal pregnancy and no history of hypertension or preeclampsia. She had an unremarkable prenatal course and her blood pressure prenatally ranged from 98/62 mm Hg to 130/80 mm Hg one week before delivery. Urine protein was zero or trace at all visits. She delivered a healthy 2,670 g (5 lb, 8 oz) male infant at term. Blood pressures immediately postpartum were mostly 120s to 130s/60s to 70s mm Hg with occasional pressures of 140 to 150/80 to 90 mm Hg.

Eight days after delivery, the patient awoke with a severe bilateral frontal headache and blurry vision. Over several hours, this progressed to acute bilateral cortical blindness. Initial evaluation showed blood pressure of 169/99 but without proteinuria. Subsequent 24-hour urine collection showed 0.28 grams protein. Computed axial tomography of the brain demonstrated bilateral low attenuation lesions in the cerebral hemispheres; magnetic resonance imaging revealed diffuse altered T2 signals in a posterior distribution. Cerebral angiogram was normal. Twenty hours after the onset of symptoms the patient developed altered mental status and had two tonic-clonic seizures, at which point she was treated with phenytoin (Dilantin) and magnesium.

The patient's headache and vision quickly improved and by 48 hours her vision had returned to 20/20 acuity. Her blood pressure continued to be elevated throughout her hospital stay, at one point reaching 200/110 mm Hg. Three days after admission, she was discharged home on metoprolol.

Preeclampsia in pregnancy is defined as new-onset elevated blood pressure (>140/90 mm Hg) along with proteinuria after 20 weeks of gestation. (1,2) Severe cases may progress to eclampsia characterized by seizures. A multicenter review (3) of pre-eclampsia found up to one third of cases developed postpartum with 80 percent of these occurring three to 14 days after delivery. One case report (4) describes onset 26 days after delivery.

Although visual changes such as blurry vision or scotoma are common, they may be more typical of late-onset disease. (3,5) One study reported visual symptoms in 44 percent of patients with late-onset pre-eclampsia. (3) Acute cortical blindness has been estimated to occur in 1 to 3 percent of patients with eclampsia, although a review of 15 cases noted a prevalence of 15 percent. (5) Our patient was similar to patients in that case series including the transient nature of visual loss (four hours to eight days in their review) and mental status changes (three of their 15 patients) but had minimal urine protein and relatively mild hypertension on initial presentation.

Because 90 percent of women presenting with late postpartum preeclampsia have a headache and close to one half have some type of visual disturbance, physicians providing obstetric care should be alert for these symptoms as an unusual presentation of this disease. This case demonstrates that preeclampsia is less common in multiparous patients, but it can be severe when it develops.

KATHERINE J. GOLD, M.D., M.S.W.

Dept. of Family Medicine University of Michigan 1500 E. Medical Center Dr. Rm. L2003 Box 0239 Ann Arbor, MI 48109-0239

CHRISTOPHER BARNES, D.O.

Dept. of Family Medicine University of Michigan

JESSICA LALLEY, M.D.

Dept. of Obstetrics and Gynecology University of Michigan

THOMAS L. SCHWENK, M.D.

Dept. of Family Medicine University of Michigan

REFERENCES

(1.) ACOG Committee on Obstetric Practice. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. No. 33, January 2002. American College of Obstetricians and Gynecologists. Obstet Gynecol 2002;99:159-67.

(2.) Lipstein H, Lee CC, Crupi RS. A current concept of eclampsia. Am J Emerg Med 2003;21:223-6.

(3.) Chames MC, Livingston JC, Ivester TS, Barton JR, Sibai BM. Late postpartum eclampsia: a preventable disease? Am J Obstet Gynecol 2002;186:1174-7.

(4.) Delefosse D, Samain E, Helias A, Regimbeau JM, Deval B, Farah E, et al. Late onset of cortical blindness in a patient with severe preeclampsia related to retained placental fragments. Anesthesiology 2003;98:261-3.

(5.) Cunningham FG, Fernandez CO, Hernandez C. Blindness associated with preeclampsia and eclampsia. Am J Obstet Gynecol 1995;172:1291-8.

COPYRIGHT 2005 American Academy of Family Physicians
COPYRIGHT 2005 Gale Group

Return to Dilantin
Home Contact Resources Exchange Links ebay